Discovery of tetrahydro-ß-carboline derivatives as a new class of phosphodiesterase 4 inhibitors
- 363 Downloads
Phosphodiesterase 4 is the primary enzyme responsible for degradation of the second messenger cAMP in many of the cells releasing proinflammatory mediators. Inhibition of this enzyme could help in the management of various inflammatory conditions such as asthma, chronic obstructive pulmonary disorder, arthritis, and psoriasis. In this study, two novel series of tetrahydro-β-carbolines were designed by combining the pharmacophoric features of both tadalafil and piclamilast. Twenty-two compounds were synthesized and assessed for Phosphodiesterase 4 inhibition, four of them showed superior activity to the reference compound IBMX. Docking studies showed that the prepared compounds interact with the crucial Gln443 with variable interactions with the hydrophobic pocket Q2. This is the first report of tetrahydro-β-carbolines as a scaffold for Phosphodiesterase 4 inhibition. Currently, further optimization of the substituents is carried out to fine-tune the hydrophobic interactions and enhance the potency of this novel series of inhibitors.
KeywordsCOPD Asthma PDE4 β-Carboline Docking
This study was entirely funded by the Science and Technology Development Fund (STDF), Egypt, Grant #4711, awarded to the Principal Investigator Dr. Mohamed A. Helal. The authors would like to thank Dr. Khaled M. Darwish, Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, for his insights in the design of the target compounds and during the synthetic steps.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- Annamala MK, Inampudi KK, Guruprasad L (2007) Docking of phosphonate and trehalose analog inhibitors into M. tuberculosis mycolyltransferase Ag85C: Comparison of the two scoring fitness functions GoldScore and ChemScore, in the GOLD software. Bioinformation 1(9):339–350CrossRefPubMedPubMedCentralGoogle Scholar
- Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 12(12):2233–2247CrossRefPubMedGoogle Scholar
- Daugan A, Grondin P, Ruault C, de Gouville ACLeMonnier, Coste H, Linget JM, Kirilovsky J, Hyafil F, Labaudiniere R (2003) The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1’,2’:1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem 46(21):4533–4542CrossRefPubMedGoogle Scholar
- De Savi C, Cox RJ, Warner DJ, Cook AR, Dickinson MR, McDonough A, Morrill LC, Parker B, Andrews G, Young SS, Gilmour PS, Riley R, Dearman MS (2014) Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD. J Med Chem 57(11):4661–4676CrossRefPubMedGoogle Scholar
- Kulick CV, Gutherz SB, Beck VC, Medvedeva N, Soper C, Forcelli PA (2014) Profile of anticonvulsant action of levetiracetam, tiagabine and phenobarbital against seizures evoked by DMCM (methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate) in neonatal rats. Eur J Pharmacol 743:63–68CrossRefPubMedPubMedCentralGoogle Scholar
- Richmond BW, Brucker RM, Han W, Du RH, Zhang Y, Cheng DS, Gleaves L, Abdolrasulnia R, Polosukhina D, Clark PE, Bordenstein SR, Blackwell TS, Polosukhin VV (2016) Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun 7:11240CrossRefPubMedPubMedCentralGoogle Scholar
- Sunden F, AlSadhan I, Lyubimov AY, Ressl S, Wiersma-Koch H, Borland J, Brown Jr. CL, Johnson TA, Singh Z, Herschlag D (2016) Mechanistic and evolutionary insights from comparative enzymology of phosphomonoesterases and phosphodiesterases across the alkaline phosphatase superfamily. J Am Chem Soc 138(43):14273–14287CrossRefPubMedPubMedCentralGoogle Scholar